169 related articles for article (PubMed ID: 28045540)
1. Characterization of Pegylated Liposomal Mitomycin C Lipid-Based Prodrug (Promitil) by High Sensitivity Differential Scanning Calorimetry and Cryogenic Transmission Electron Microscopy.
Wei X; Patil Y; Ohana P; Amitay Y; Shmeeda H; Gabizon A; Barenholz Y
Mol Pharm; 2017 Dec; 14(12):4339-4345. PubMed ID: 28045540
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic Studies of a Prodrug of Mitomycin C in Pegylated Liposomes (Promitil(®)): High Stability in Plasma and Rapid Thiolytic Prodrug Activation in Tissues.
Amitay Y; Shmeeda H; Patil Y; Gorin J; Tzemach D; Mak L; Ohana P; Gabizon A
Pharm Res; 2016 Mar; 33(3):686-700. PubMed ID: 26572644
[TBL] [Abstract][Full Text] [Related]
3. Development of Promitil®, a lipidic prodrug of mitomycin c in PEGylated liposomes: From bench to bedside.
Gabizon A; Shmeeda H; Tahover E; Kornev G; Patil Y; Amitay Y; Ohana P; Sapir E; Zalipsky S
Adv Drug Deliv Rev; 2020; 154-155():13-26. PubMed ID: 32777239
[TBL] [Abstract][Full Text] [Related]
4. Targeting of pegylated liposomal mitomycin-C prodrug to the folate receptor of cancer cells: Intracellular activation and enhanced cytotoxicity.
Patil Y; Amitay Y; Ohana P; Shmeeda H; Gabizon A
J Control Release; 2016 Mar; 225():87-95. PubMed ID: 26809007
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic efficacy of a lipid-based prodrug of mitomycin C in pegylated liposomes: studies with human gastro-entero-pancreatic ectopic tumor models.
Gabizon A; Amitay Y; Tzemach D; Gorin J; Shmeeda H; Zalipsky S
J Control Release; 2012 Jun; 160(2):245-53. PubMed ID: 22134116
[TBL] [Abstract][Full Text] [Related]
6. Reduced toxicity and superior therapeutic activity of a mitomycin C lipid-based prodrug incorporated in pegylated liposomes.
Gabizon AA; Tzemach D; Horowitz AT; Shmeeda H; Yeh J; Zalipsky S
Clin Cancer Res; 2006 Mar; 12(6):1913-20. PubMed ID: 16551877
[TBL] [Abstract][Full Text] [Related]
7. Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy.
Gabizon A; Ohana P; Amitay Y; Gorin J; Tzemach D; Mak L; Shmeeda H
Cancer Drug Resist; 2021; 4(2):463-484. PubMed ID: 35582027
[No Abstract] [Full Text] [Related]
8. Pegylated liposomal mitomycin C prodrug enhances tolerance of mitomycin C: a phase 1 study in advanced solid tumor patients.
Golan T; Grenader T; Ohana P; Amitay Y; Shmeeda H; La-Beck NM; Tahover E; Berger R; Gabizon AA
Cancer Med; 2015 Oct; 4(10):1472-83. PubMed ID: 26172205
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of mitomycin-c lipidic prodrug entrapped in liposomes and clinical correlations in metastatic colorectal cancer patients.
Gabizon AA; Tahover E; Golan T; Geva R; Perets R; Amitay Y; Shmeeda H; Ohana P
Invest New Drugs; 2020 Oct; 38(5):1411-1420. PubMed ID: 31955309
[TBL] [Abstract][Full Text] [Related]
10. Insights into composition/structure/function relationships of Doxil® gained from "high-sensitivity" differential scanning calorimetry.
Wei X; Cohen R; Barenholz Y
Eur J Pharm Biopharm; 2016 Jul; 104():260-70. PubMed ID: 27106607
[TBL] [Abstract][Full Text] [Related]
11. Novel lipophilic SN38 prodrug forming stable liposomes for colorectal carcinoma therapy.
Xing J; Zhang X; Wang Z; Zhang H; Chen P; Zhou G; Sun C; Gu N; Ji M
Int J Nanomedicine; 2019; 14():5201-5213. PubMed ID: 31371956
[No Abstract] [Full Text] [Related]
12. Pegylated Liposomal Mitomycin C Lipidic Prodrug in Combination With External Beam Radiation Therapy in Patients With Advanced Cancer: A Phase 1B Study.
Sapir E; Pfeffer R; Wygoda M; Purim O; Levy A; Corn B; Amitay Y; Ohana P; Gabizon A
Int J Radiat Oncol Biol Phys; 2023 Sep; 117(1):64-73. PubMed ID: 36933845
[TBL] [Abstract][Full Text] [Related]
13. Temoporfin-loaded liposomes: physicochemical characterization.
Kuntsche J; Freisleben I; Steiniger F; Fahr A
Eur J Pharm Sci; 2010 Jul; 40(4):305-15. PubMed ID: 20412853
[TBL] [Abstract][Full Text] [Related]
14. Liposomal formulation of a glycerolipidic prodrug for lymphatic delivery of didanosine via oral route.
Lalanne M; Andrieux K; Paci A; Besnard M; Ré M; Bourgaux C; Ollivon M; Desmaele D; Couvreur P
Int J Pharm; 2007 Nov; 344(1-2):62-70. PubMed ID: 17616448
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Evaluation of Promitil, a Radiation-Responsive Liposomal Formulation of Mitomycin C Prodrug, in Chemoradiotherapy.
Tian X; Warner SB; Wagner KT; Caster JM; Zhang T; Ohana P; Gabizon AA; Wang AZ
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):547-55. PubMed ID: 27681751
[TBL] [Abstract][Full Text] [Related]
16. Calorimetry and Langmuir-Blodgett studies on the interaction of a lipophilic prodrug of LHRH with biomembrane models.
Sarpietro MG; Accolla ML; Santoro N; Mansfeld FM; Pignatello R; Toth I; Castelli F
J Colloid Interface Sci; 2014 May; 421():122-31. PubMed ID: 24594040
[TBL] [Abstract][Full Text] [Related]
17. Ex-vivo activation of a liposomal prodrug of mitomycin C by human tumors.
Dorot S; Tankel J; Doviner V; Shmeeda H; Amitay Y; Ohana P; Dagan A; Ben-Haim M; Reissman P; Gabizon A
Cancer Chemother Pharmacol; 2022 Aug; 90(2):109-114. PubMed ID: 35802145
[TBL] [Abstract][Full Text] [Related]
18. Chemo-Radiotherapy of Oligometastases of Colorectal Cancer With Pegylated Liposomal Mitomycin-C Prodrug (Promitil): Mechanistic Basis and Preliminary Clinical Experience.
Tahover E; Bar-Shalom R; Sapir E; Pfeffer R; Nemirovsky I; Turner Y; Gips M; Ohana P; Corn BW; Wang AZ; Gabizon AA
Front Oncol; 2018; 8():544. PubMed ID: 30534533
[TBL] [Abstract][Full Text] [Related]
19. Phase structures of a hydrated anionic phospholipid composition containing cationic dendrimers and pegylated lipids.
Khopade AJ; Shenoy DB; Khopade SA; Jain NK
Langmuir; 2004 Aug; 20(18):7368-73. PubMed ID: 15323476
[TBL] [Abstract][Full Text] [Related]
20. Practical aspects in size and morphology characterization of drug-loaded nano-liposomes.
Peretz Damari S; Shamrakov D; Varenik M; Koren E; Nativ-Roth E; Barenholz Y; Regev O
Int J Pharm; 2018 Aug; 547(1-2):648-655. PubMed ID: 29913218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
